3M rolls out plasma coating and face seal tech for pMDIs

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmacology Pharmaceutical drug

3M’s drug delivery unit believes its new plasma coating and face seal valve pMDI technologies help protect APIs and will mean that more drugs can be delivered via inhalation.

While the replacement of CFC propellants in inhalation systems with hydrofluoroalkane (HFA) less environmentally damaging compounds has obvious benefits, for drug formulators the change has posed some challenges.

One of the most common of these is that in certain HFA formulations active pharmaceutical ingredients (APIs) can become degraded when they contact the interior surfaces of pressurised metered dose inhaler (pMDI) systems, impacting on their efficacy.

3M’s solution for this is plasma coating. The firm explained that the technique involves applying an ultra-thin film to all solid components of pMDI, thereby protecting the API.

The company, which showcased the technology at the Respiratory Drug Delivery Conference (RDD) held in Portugal last week, said that laboratory analysis had demonstrated a significant decrease in API degradation and deposition.

3M’s valve face seal technology, also launched at RDD is designed to eliminate the need to prime an inhaler by collecting the dose as the inhaler is fired, which is an approach used by traditional pMDI systems.

The firm explained that over-time, priming in traditional systems can become less effective and even result in the delivery of incomplete doses, “which is why patients are advised to prime these inhalers by firing an uninhaled shot before use​.

The 3M Face Seal Valve eliminates the need for this extra step, simplifying the process for patients and making compliance easier. The technology helps ensure patients receive a full dose of medication with every use, including single shot products, resulting in more satisfied patients and prescribers​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers